Organophosphorus agents (OP) are used as pesticides in developing countries and acute poisoning is common because of insufficient control, poor storage, ready availability, and inadequate education among farmers.
It is estimated about 200,000 people die each year across the world from OP poisoning, through occupational exposure, unintentional use and misuse, mostly in developing countries like India, Pakistan, and Sri Lanka.
OPs include compounds like Tabun, which was developed in 1936 by German scientists during World War II, Sarin, Soman, Cyclosarin, VX, and VR.
Using a modified human enzyme, researchers in the new study created a "bioscavenger" which was found to protect mice against the nerve agent VR and showed no lasting effects.
In studies performed at the Institute of Bioorganic Chemistry in Pushchino, Russia, a total of eight mice were treated with the new enzyme after being subjected to enough of the VR agent to kill several of the animals - about 63 mg per kilogramme - and all survived.
"This current publication describes a novel method to generate a bioscavenger for the Russian VR organophosphorus agent with the key property of being long-acting in the bloodstream," researcher Professor Mike Blackburn from the University of Sheffield said in a statement.
"That has been achieved by a combination of chemical surface modification (polysialylation) and biotechnology of production (through the use of an in vitro CHO-based expression system employing genes encoding butyrylcholinesterase and a proline-rich peptide under special promoter control)," Blackburn said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
